Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research report on Thursday, November 14th.

Trevena Trading Up 3.0 %

NASDAQ:TRVN opened at $1.74 on Wednesday. The firm has a market capitalization of $1.50 million, a PE ratio of -0.04 and a beta of 1.05. Trevena has a 1 year low of $1.13 and a 1 year high of $17.50. The firm’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $3.14.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million during the quarter. As a group, analysts anticipate that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.